If I understand correctly:

12 million potential patients in the top 8 markets could be treated for one of the 3 diseases being tested in the BETonMACE trial.

From what I understand it seems that between $5000-$6000 per year per patient for treatment.

So if we just capture 10% of market or 1.2 million patients:

1,200,000 X $5000 = $6 billion

$6 billion / 200 millions shares (balpark shares outstanding) = 30 times,... 

,... and that is just for 10%,... and that is just for the top 8 markets,... and that is just for 3 indications,... and it seems there are at least 20 more!

Looking foward to when the US markets get to hear what the analysts say once Top-Line results are announced!!